HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

eltenac

structure given in first source

Also Known As:

Telzenac

Networked: 7 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Aniline Compounds: 46
    - eltenac: 7
- Sulfur Compounds: 278
  - Thiophenes: 257
    - eltenac: 7
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Thiophenes: 257
    - eltenac: 7

Experts

1.	Baudler, Monika: 1 article (09/2008)
2.	Brehm, Christoph: 1 article (09/2008)
3.	Dullweber, Frank: 1 article (09/2008)
4.	Figala, Volker: 1 article (09/2008)
5.	Herrmann, Michael: 1 article (09/2008)
6.	Klein, Thomas: 1 article (09/2008)
7.	Prinz, Walter: 1 article (09/2008)
8.	Germann, Paul-Georg: 1 article (07/2003)
9.	Häfner, Dietrich: 1 article (07/2003)
10.	Ibrahim, Merdol: 1 article (07/2003)

Related Diseases

1.	Body Weight (Weight, Body) 11/01/1998 - "Eltenac (50 mg/ml) was administered IV at a dosage of 0.5 mg/kg of body weight every 24 hours for days 0 through 4. On days 0 and 4, blood samples were collected before, then periodically for 8 hours after eltanac administration. " 03/01/1997 - "To titrate a clinically effective eltenac dosage (0.1, 0.5, and 1.0 mg/kg of body weight), compared with vehicle only, and to compare efficacy of the most effective eltenac dosage with that of 1.1 mg of flunixin meglumine/kg. 40 healthy horses, ranked after model induction on the basis of lameness severity, were randomly assigned to 5 treatment groups, with 4 replicates of 10 horses each. "
2.	Knee Osteoarthritis 04/01/2001 - "Efficacy and safety of eltenac gel in the treatment of knee osteoarthritis." 01/01/1997 - "Local NSAID gel (eltenac) in the treatment of osteoarthritis of the knee. " 01/01/1997 - "In a randomized, double blind, multicentre study with 4 weeks follow-up of 290 patients with osteoarthritis of the knee joint, a topical NSAID (eltenac) was compared with oral diclofenac and placebo. "
3.	Pain (Aches) 06/01/1991 - "Swelling was assessed by measuring the diameter of the external preputial fold using two methods: callipers and a rating scale of 0 to 3. Additionally, photographs were taken on days 1, 2 and 4. Compared with the placebo treatment, eltenac inhibited pain and swelling significantly. " 06/01/1991 - "Compared with the placebo treatment, eltenac produced significant pain relief after a single i.v. injection for a period of 24 h. " 03/01/1997 - "Thus, a dose-response plateau for eltenac was reached at 0.5 mg/kg. Comparison with flunixin meglumine at a dosage of 1.1 mg/kg did not indicate significant differences between the 2 treatment groups at the pivotal time of 96 hours for carpal circumference, carpal flexion angle, stride length, carpal hyperthermia, and signs of carpal pain. "
4.	Acute Lung Injury 07/01/2003 - "The effects of additional i.v. therapy with a cyclooxygenase-inhibitor Eltenac to a recombinant surfactant protein C (rSP-C) based surfactant were investigated in a rat lung lavage model of acute lung injury. "
5.	Edema (Dropsy) 09/15/2008 - "In a rat paw edema model, these compounds showed reduction of edema volume in the range of 36-45% at 10 mg/kg (Eltenac 52%, Diclofenac 51%). "

Related Drugs and Biologics

1.	flunixin meglumine (Banamine)
2.	Diclofenac (SR 38)
3.	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)
4.	Cyclooxygenase Inhibitors
5.	Surface-Active Agents (Surfactants)
6.	Protein C
7.	Dihydrotachysterol (AT 10)

Related Therapies and Procedures

1.	Therapeutics